Nuva
-
Better-than-expected profits lift NuVasive shares
NuVasive reported better-than-expected profit for the second quarter and executives boosted their predictions for full-year earnings as sales surged for…
Read More » -
Needham & Company Reiterates a ‘Strong Buy’ on NuVasive (NUVA)
Needham & Company reiterates a ‘Strong Buy’ rating on NuVasive Inc. (Nasdaq: NUVA), price target $60. Needham analyst says, “We expect…
Read More » -
NuVasive Reports First Quarter 2010 Financial Results
NuVasive, Inc. , a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced…
Read More » -
NuVasive, Inc. appointed Michael Lambert to the position of Chief Financial Officer and Executive Vice President
On October 19, 2009, NuVasive, Inc. (the “Company”) appointed Michael Lambert to the position of Chief Financial Officer and Executive…
Read More »